Octave® Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate  Biomarker Test for Parkinson’s Disease. Learn More

Octave at ACTRIMS 2023!

February 23 – 25, 2023
San Diego, California

The conference is over, but the journey continues.

Check out Octave’s announcements and each of the 9 posters presented at
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)!
Event Coverage

Gauging MS Disease Activity Through Octave’s MSDA Test: Taylor Gonyou, DO

NeurologyLive

Octave partner, Dr. Taylor Gonyou, DO, a multiple sclerosis fellow at Michigan Institute for Neurologic Disorders (MIND), sat down with NeurologyLive at ACTRIMS to provide perspective on the clinical utility and advantages of Octave’s multi-protein test that assesses multiple sclerosis disease activity (MSDA).

Read Article

ACTRIMS 2023

VJNeurology

Ferhan Qureshi, Vice President of Biomarker Product Development at Octave, spoke to VJNeurology and shared some findings about:

  • Serum biomarkers of brain atrophy in MS
  • Serum proteins associated with glial cell injury, MRI measures & neuropsychological outcomes in MS
  • Real-world use of the MSDA test: a case series

Watch Now

Varied interpretation of MRI reports by neurologists may lead to differences in MS care

Healio

Variations in satisfaction and confidence in MRI reports may lead to significant variability in the clinical decisions made by neurologists specializing in multiple sclerosis (MS) care, according to a poster from Octave shared at ACTRIMS 2023.

Read Article

Utilizing Biomarker Panels to Effectively Gauge, Manage Multiple Sclerosis

NeurologyLive

Octave partner, Dr. Taylor Gonyou, DO, a multiple sclerosis fellow at Michigan Institute for Neurologic Disorders (MIND), spoke with NeurologyLive at ACTRIMS to detail Octave’s proteomic biomarker panel that gauges multiple sclerosis disease activity, with potential to impact clinical decision-making.

Read Article

Company News

Octave Presents Data from Nine Company and Partner Abstracts at ACTRIMS Forum 2023

Business Wire

Real-world data sets show components of value-based care, use of Octave’s Multiple Sclerosis Disease Activity (MSDA) test and deep scan biomarker screening capabilities to evaluate evidence of disability, disease activity and disease progression.

Read Article